Delta-Fly Pharma, Inc.

Delta-Fly Pharma develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia.

Its portfolio also includes DFP-14323, which is in phase III clinical trial to treat lung cancer, DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer, DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer, DFP-14927 that is in phase I for the treatment of hematologic cancer, and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Incorporated in 2010, the company is headquartered in Tokushima, Japan.